Compare CARR & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CARR | IQV |
|---|---|---|
| Founded | 2019 | 1982 |
| Country | United States | United States |
| Employees | N/A | 93000 |
| Industry | Industrial Machinery/Components | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.4B | 43.1B |
| IPO Year | 2020 | 2013 |
| Metric | CARR | IQV |
|---|---|---|
| Price | $53.72 | $267.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 16 |
| Target Price | $70.62 | ★ $227.13 |
| AVG Volume (30 Days) | ★ 5.6M | 1.3M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.55% | N/A |
| EPS Growth | N/A | ★ 4.67 |
| EPS | 0.28 | ★ 1.61 |
| Revenue | ★ $21,747,000,000.00 | $9,739,000,000.00 |
| Revenue This Year | $2.91 | $6.77 |
| Revenue Next Year | $5.37 | $5.89 |
| P/E Ratio | $194.25 | ★ $167.35 |
| Revenue Growth | N/A | ★ 41.60 |
| 52 Week Low | $50.24 | $154.50 |
| 52 Week High | $76.76 | $273.88 |
| Indicator | CARR | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 27.12 | 63.35 |
| Support Level | $51.40 | $252.53 |
| Resistance Level | $54.50 | $271.80 |
| Average True Range (ATR) | 1.75 | 6.26 |
| MACD | -0.22 | -0.85 |
| Stochastic Oscillator | 12.44 | 67.87 |
Carrier Global, spun out of United Technologies in 2020, manufactures and services commercial and residential HVAC systems and transportation refrigeration solutions under its flagship Carrier brand, as well as Bryant, Payne, Heil, and others across various price points. In 2024, Carrier acquired Viessmann Climate Solutions to expand its footprint in Europe with heat pumps, boilers, and solar PV equipment. Proceeds from the sale of Carrier's fire and security (Honeywell) and commercial refrigeration (Haier) businesses reduced debt and focused the company on global HVAC and refrigeration solutions. Carrier generates 75% of sales from equipment and 25% from parts and services. The company derives 50% of revenue from the US, 30% from Europe, and 20% from the Asia-Pacific region.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.